Glenmark gets FDA’s blessing for two generics
Glenmark Pharmaceuticals has received the Food and Drug Administration’s nod for for fluocinolone acetonide oil, 0.01%, ear drops
The product is a generic version of Hill Dermaceuticals’ DermOtic Oil, 0.01% ear drops.
The product had a market value of approximately $18.1 million for the 12 month period ending October 2018, according to IQVIA data.
Glenmark also received the FDA green light for hydrocortisone valerate ointment, 0.2%.
The product is the generic version of Sun Pharmaceutical’s Westcort ointment, 0.2%.
Westcort ointment, 0.2% had a market value of about $11.1 million for the 12 month period ending October 2018, according to IQVIA data.
Paramount Rx reports $400 million in 2018 patient savings
Paramount Rx, a prescription benefits manager, saved customers more than $400 million on their prescriptions in 2018 through its Community Cares Rx prescription discount program.
The program’s free prescription discount card helps provide immediate savings to millions of underinsured and uninsured American families.
“As the new year approaches, many of our customers are facing important health care decisions and contending with increased premiums, cost sharing increases and deductible resetting,” Paramount Rx senior vice president of provider relations Ron Richmond said. “By eliminating the high fees typically associated with prescription discount cards, we are able to pass significantly more savings along to customers than many other programs in the marketplace.”
The Community Cares Rx card is accepted at more than 57,000 pharmacy locations across the country.
Online tools allow program participants to locate a pharmacy and research drug pricing and availability.
Paramount Rx also invested in communities across the country, including funding vaccination programs in Texas, supporting diabetes education initiatives in Minnesota and donating to community-based food charities in Florida.
Mylan gets FDA green light for generic Canasa
The Food and Drug Administration has approved Mylan’s mesalamine rectal suppository, 1000mg.
Mesalamine rectal suppository is the first generic version of Allergan’s Canasa rectal suppository, 1000 mg.
The product is for the treatment of mildly to moderately active ulcerative proctitis.
Mesalamine rectal suppository, 1000 mg had a market value of approximately $263 million for the 12 months ending October 31, 2018, according to IQVIA.